1.1000 +0.02 (1.85%)
After hours: 4:04PM EDT
|Bid||1.0700 x 800|
|Ask||1.1000 x 1000|
|Day's Range||1.0600 - 1.1500|
|52 Week Range||0.9300 - 2.4500|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Axovant Gene Therapies Ltd. (NASDAQ:AXGT) shareholders should be happy to see the share price up 19% in the last quarter. But only the myopic could ignore the astounding decline over three years. The share price has sunk l...
Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...
Axovant Sciences Ltd NASDAQ/NGS:AXGTView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for AXGT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. Over the last one-month, outflows of investor capital in ETFs holding AXGT totaled $214 million. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Smaller gene therapy biotechs are taking the spotlight given the M&A interest surrounding them. One such gene therapy company saw its shares rallying by more than 30 percent Monday following the release ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies thatRead More...